Skybiotech Healthcare ratifies name change compliance, approves FY26 accounts
- Skybiotech Healthcare ratified rectification of SEBI LODR non-compliance regarding its name change from Kapil Cotex
- Audited standalone and consolidated financial statements for FY26 were adopted by shareholders
- M/s. SPD & Associates appointed as statutory auditor replacing previous engagement
- Mr. Prakashchandra Rathi re-appointed as director retiring by rotation

*this image is generated using AI for illustrative purposes only.
Skybiotech Healthcare ratified the rectification of a procedural non-compliance related to its name change from Kapil Cotex Limited during its 43rd Annual General Meeting (AGM) held on September 30, 2026. The meeting also adopted the audited financial statements for FY26 and appointed a new statutory auditor.
Name change compliance rectified
The company had changed its name from Kapil Cotex Limited to Skybiotech Healthcare Limited via a Special Resolution at the AGM held on September 25, 2025. However, the certificate from a Practicing Chartered Accountant confirming compliance with Regulation 45(1) of the SEBI LODR Regulations was inadvertently not circulated with the notice for that approval.
To address this oversight, the company furnished an undertaking to BSE Limited to rectify the non-compliance under Regulation 45(3). During the current AGM, the Chairman placed the required CA certificate before the members. The shareholders took note of the certificate and ratified the actions taken by the company, thereby approving the rectification of the procedural lapse.
Key resolutions passed
Shareholders adopted both standalone and consolidated audited financial statements along with the reports of the Board and Auditor for the year ended March 31, 2026. Additionally, Mr. Prakashchandra Rathi (DIN: 01393087) was re-appointed as a director, retiring by rotation and offering himself for re-appointment as he is eligible.
The appointment of M/s. SPD & Associates, Chartered Accountants (FRN: 139118W), marks a change in the statutory audit engagement for the company. This resolution was passed as an ordinary resolution by the members present.
| Resolution Type | Matter | Status |
|---|---|---|
| Ordinary | Adoption of Standalone Audited Financial Statements (FY26) | Approved |
| Ordinary | Adoption of Consolidated Audited Financial Statements (FY26) | Approved |
| Ordinary | Re-appointment of Mr. Prakashchandra Rathi as Director | Approved |
| Ordinary | Appointment of SPD & Associates as Statutory Auditor | Approved |
| Ordinary | Ratification of name change compliance rectification | Approved |
Meeting proceedings and attendance
The AGM commenced at 11:00 am at the company's registered office in Chh. Sambhaji Nagar, Maharashtra, and concluded at 12:40 pm on September 30, 2026. The Company Secretary reported that as on the cut-off date of September 23, 2026, there were 649 members in the company. With seven members present in person, the requisite quorum under Section 103 of the Companies Act, 2013, was satisfied.
Directors present included Managing Director Poonam Prakash Rathi, Director and CFO Prakashchandra Rathi, Independent Director Yogesh Chandak, and Non-Executive Director Vijay Chitlange. Leave of absence was granted to Independent Directors Mr. Rakesh Ramswaroop Somani and Jagdish Manohar Mantri due to pre-occupation.
Historical Stock Returns for Skybiotech Healthcare
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| 0.0% | -0.97% | -2.50% | -15.77% | 0.0% | +277.42% |
How will the transition from Kapil Cotex to Skybiotech Healthcare impact the company's strategic direction and revenue mix in the upcoming fiscal years?
What specific changes in audit scope or methodology can investors expect with the appointment of SPD & Associates as the new statutory auditor?
Given the low shareholder attendance and quorum satisfaction, how might this affect future corporate governance ratings or institutional investor confidence?































